GlaxoSmithKline on Thursday said that a lab analysis of the antibody-based COVID-19 therapy it is developing with U.S. partner Vir has shown the drug is effective against the new Omicron variant. In a statement, the British drugmaker said that lab tests and a study on hamsters have demonstrated the sotrovimab antibody cocktail to work against viruses that were bio-engineered to carry a number of hallmark mutations of the Omicron variant.